Clinical Trials Logo

Hematologic Diseases clinical trials

View clinical trials related to Hematologic Diseases.

Filter by:

NCT ID: NCT06350526 Not yet recruiting - Clinical trials for Hematologic Diseases

Radiological Characterization of Pulmonary Involvement in Patients With Hematological Diseases

Start date: May 1, 2024
Phase:
Study type: Observational

Hematologic malignancies are heterogeneous groups of neoplasia, with frequent pulmonary complications. These complications may be secondary to the patient's comorbidities, to the hemopathy itself, or its treatments. Divided into infectious and non-infectious complications, the etiologies are numerous and varied. This makes the diagnostic approach complex for the clinicians

NCT ID: NCT06304194 Recruiting - Clinical trials for Hematologic Diseases

Molecular Characterizazion and Biological Samples Centralisation of Patients Affected by Oncoematolofic Pathology

Start date: July 5, 2023
Phase: N/A
Study type: Interventional

Currently, the molecular characterization of onco-hematological, onco-immunological and hematological diseases, at onset or in relapse, of patients with suspected diagnosis afferent to the CROP centers, is done through centralization of biological samples at reference laboratories outside the Tuscany Region. In order to preserve the wealth of clinical and biological data and use it for the benefit of present and future patients treated at the CROP centers, it is useful to evaluate the feasibility of centralization and molecular typing of mutations present in tumor tissue at the IRCCS AOU Meyer Oncohematology Laboratories and subsequently the analysis of clinical data from patients with diseases not under study to lay the foundations of a translational database that can then be associated with a biobank in the future. This will enable a targeted contribution to pediatric oncohematology research, investing in possible targeted therapies with those patient subgroups that benefit from personalized disease assessment in mind. The goal of the project is to improve the regional infrastructure dedicated to organized data collection and management of biological samples in adequate time resulting in better and more comprehensive data collection.

NCT ID: NCT06294691 Not yet recruiting - Clinical trials for Acute Graft-versus-host Disease

Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases

Start date: March 1, 2024
Phase: Phase 3
Study type: Interventional

To observe the effect of stem cell infusion on the development of acute graft- versus-host disease (aGVHD) in patients with nonmalignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT)

NCT ID: NCT06291415 Recruiting - Hemorrhage Clinical Trials

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

Start date: April 2, 2024
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter study to evaluate the safety, tolerability, and efficacy of HMPL-523 in adult subjects with ITP.

NCT ID: NCT06286228 Not yet recruiting - Multiple Myeloma Clinical Trials

Registry of Haploidentical Hematopoietic Stem Cell Transplantation in Adult With Hematologic Disease

Haplo
Start date: April 1, 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to register hematologic patients with haploidentical hematopoietic stem cell transplantation (haploHSCT). The main questions it aims to answer are: - 1-year progression free survival rate - 1-year overall survival rate - Graft-versus-host free relapsed free survival at 30-day, 100-day, 180-day and 1-year - Chronic Graft-versus-host free relapsed free survival at 180-day and 1-year - Rate of Neutrophil and platelet engraftment - Efficacy of donor specific antibody desensitization - Relapsed rate - Primary and late graft failure - Safety and complication of haploHSCT - Complication of viral, bacterial, and fungal infection - Viral reactivation - Comparison outcomes between matched sibling donor (MSD) HSCT and matched unrelated donor (MUD) HSCT - Comparison cost-effectiveness of treatment between matched sibling donor (MSD) HSCT and matched unrelated donor (MUD) HSCT Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.

NCT ID: NCT06281496 Not yet recruiting - Clinical trials for Hematological Diseases

AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation

AlloCare
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

A developed multimodal intervention targeting late effects in survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) will be evaluated in a two-arm randomized controlled trial with an internal pilot phase.

NCT ID: NCT06277479 Enrolling by invitation - Clinical trials for Hematological Diseases

Late Effects and HRQoL in Survivors of Allo-HSCT - a Cross Sectional Study

Start date: March 2024
Phase:
Study type: Observational

The cross-sectional study aims to describe the burden of late effects and survivorship-specific health-related quality of life in a nationwide cohort of patients treated with allo-HSCT in Denmark. Further, identify demographic, medical or personal factors associated with better self-reported health and quality of life.

NCT ID: NCT06271252 Recruiting - Clinical trials for Cardiovascular Diseases

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Start date: April 3, 2024
Phase: Phase 1
Study type: Interventional

The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study

NCT ID: NCT06227468 Recruiting - Healthy Clinical Trials

A Clinical Study to Map the HLA Genomic Region in the Greek Population

GENESIS
Start date: December 12, 2023
Phase:
Study type: Observational

The aim of GENESIS clinical study is to map the HLA genomic region in the Greek population and evaluate possible correlations with selected underlying diseases.

NCT ID: NCT06222164 Not yet recruiting - Clinical trials for Hematologic Diseases

The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research

Start date: March 30, 2024
Phase:
Study type: Observational

Acquire residual human specimens and/or samples from patient samples which were sent for testing at LabPMM, LLC for Clinical Research